Indivior PLC announced on January 26, 2026 that it has completed its redomiciliation from the United Kingdom to the United States. The transaction created a new Delaware corporation, Indivior Pharmaceuticals, Inc., as the parent company, while the former Indivior PLC was renamed Indivior Ltd. and became a wholly‑owned subsidiary.
Shareholders approved the redomiciliation at an extraordinary general meeting on December 11, 2025. On the record date of January 23, 2026, each Indivior PLC ordinary share was exchanged for one Indivior Pharmaceuticals, Inc. common share, and the last trading day for Indivior PLC shares on Nasdaq was that same day.
By becoming a U.S.‑based entity, Indivior will now be subject to U.S. Securities and Exchange Commission reporting requirements and Nasdaq exchange rules. The move is intended to streamline corporate governance, reduce regulatory complexity, and strengthen the company’s presence in the U.S. capital markets, where the majority of its revenue is generated.
Financially, Indivior’s most recent quarter showed a 2% increase in total net revenue to $314 million, with SUBLOCADE net revenue up 15% year‑over‑year to $219 million. The company has guided for 2026 total net revenue of $1.125 billion to $1.195 billion and adjusted EBITDA of $535 million to $575 million, both figures surpassing analyst expectations. Management highlighted that the redomiciliation will support the company’s focus on expanding SUBLOCADE and other opioid‑use‑disorder therapies.
Analysts responded positively to the guidance, raising price targets to $50 and $48, respectively, citing the strong outlook and the strategic benefits of a U.S. domicile. The redomiciliation is seen as a key step in aligning Indivior’s corporate structure with its primary market and operational focus.
The transition positions Indivior to potentially gain inclusion in U.S. equity indices, improve access to U.S. capital, and enhance investor confidence in its long‑term growth strategy centered on high‑margin OUD treatments.
revised_sentiment_rating
importance
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.